Detalles de la búsqueda
1.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
J Viral Hepat
; 26(9): 1127-1138, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31108015
2.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467560
3.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467591
4.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20074791
5.
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Lancet HIV
; 2(8): e319-27, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26423374
Resultados
1 -
5
de 5
1
Próxima >
>>